JAMIE DAVIDSON, M.D.
Jaime Davidson is the President of Endocrine and Diabetes Associates of Texas and a Clinical Professor of Medicine at the University of Texas Southwestern Medical School in Dallas. He is a charter member of the American Association of Clinical Endocrinologists (AACE), Treasurer of WorldWide Diabetes (a not-for-profit diabetes education organization), Trustee of the American College of Endocrinology, and a member of the Texas Department of Health Services, the Council on Obesity Diabetes Education, and the International Diabetes Federation Task Force on Epidemiology, among others. Dr. Davidson has received numerous awards, including the Harold Rifkin Award from the American Diabetes Association (ADA)and the AACE’s Outstanding Service Award for the Promotion of Endocrine Health of an Underserved Population for his work in addressing health disparities in Hispanic and Latino communities. He earned his M.D. from the National Autonomous University of Mexico.
JAN FANG, PH.D.
Jan Fang is a veteran of the biopharmaceutical industry with more than 20 years of experience, including her most recent position of Research Scientist at Amgen. She possesses extensive knowledge of and experience in multi-modality drug product development from the earliest stages through global marketing applications and has successfully led global cross-functional teams in drug product development. Additionally, Dr. Fang has experience in cGXP and regulatory compliance and filings, and she has successfully removed multiple clinical holds for her clients. She has a great track record of supporting multiple new drug applications (NDAs), investigational new drug applications (INDs), pre-approval (PAI) inspections, and post-marketing product improvement. Her experience includes stints at Amgen and Pfizer. Dr. Fang earned her Ph.D. in Chemistry from Rutgers University.
JERI EL-HAGE, PH.D.
Jeri El-Hage. Ph.D., is a regulatory and toxicology consultant with Aclairo Pharmaceutical Development Group. Previously she spent almost 20 years at the Center for Drug Evaluation and Research (CDER) at U.S. Food and Drug Administration (FDA), including leading a pharmacology/toxicology team responsible for review of applications (INDs and NDAs) for products indicated for diabetes, lipid lowering, and hormonal and metabolic disturbances. Dr. El-Hage is an expert on drugs indicated for the treatment of endocrine and metabolic diseases and has extensive experience with biotechnology, biosimilar products, and carcinogenicity study evaluation and planning. She received her Ph.D. in endocrine and reproductive physiology from Howard University College of Medicine.
ROBERT R. HENRY. M.D.
Robert R. Henry, M.D., is Professor of Medicine in the Division of Endocrinology & Metabolism at University of California San Diego (UCSD). He is also chief of the Endocrinology, Metabolism & Diabetes section and the Center for Metabolic Research at the Veterans Affairs Medical Center in San Diego. Dr. Henry received his M.D. from the University of Manitoba Medical School in Canada. He was a former president of the American Diabetes Association Medicine and Science. Dr. Henry’s many memberships and accolades include: American Association of Clinical Endocrinology, European Association for the Study of Diabetes, the Distinguished Clinical Scientist Award from the American Diabetes Association, the Mary Jane Kugal Award of the Juvenile Diabetes Research Foundation International, Frontiers in Science Award from American Association of Clinical Endocrinology, and the Banting Medal for Public Service from the American Diabetes Association, to name a few.
Roger Unger is Professor of Internal Medicine and
holds the Touchstone/West Distinguished Chair in Diabetes Research at University
of Texas Southwestern. His lab is best known for its studies of islet
physiology, including the elucidation of the roles of insulin and glucagon in regulating
normal blood glucose homeostasis and in the pathogenesis of diabetes and the
establishment of glucagon as a hormone. Recently his lab introduced the concept
of lipotoxicity, the process by which overaccumulation of lipids in obesity in
nonadipose tissues leads to diabetes and to metabolic syndrome. His group has
demonstrated the role of leptin action in preventing fat-induced islet failure
and metabolic syndrome. Dr. Unger received the Banting Medal of the American
Diabetes Association, the Rumbaugh Award of the Juvenile Diabetes Association,
the Claude Bernard Medal of the European Association for the Study of Diabetes,
and the Koch Award of the Endocrine Society. He is a member of the National
Academy of Sciences and of the American Academy of Arts and Sciences and was
Director of the Touchstone Center for Diabetes Research from 1986 until 2007. Dr.
Unger earned his M.D. from Columbia University.
SAMUEL KLEIN, M.D.
Samuel Klein specializes in Gastroenterology, Nutrition, Weight Management at Washington University’s Barnes Jewish Hospital where he serves as William H. Danforth Professor of Medicine and Nutritional Science, Director of the Center for Human Nutrition, Chief of the Division of Geriatrics and Nutritional Science, Director of the Center for Applied Research Sciences, and Director of the Weight Management Program. He is widely published in his clinical interest areas of obesity, nutrition, weight management, gastroenterology, and metabolism. Dr. Klein earned his B.S. from Brandeis University, his M.D. from Temple University Medical School, and his M.S. from Massachusetts Institute of Technology.
WILLIAM (WILL) H. DERE, M.D., FACP
Willard “Will” Dere is Professor of Internal Medicine at the University of Utah School of Medicine. Previously Dr. Dere spent 11 years in executive positions at Amgen, one of the world’s largest biopharmaceutical companies, where he has served as head of global development, head of international medical, corporate chief medical officer, and international chief medical officer. Before that, he served in numerous senior positions in endocrine research and development, regulatory affairs, and translational medicine at Eli Lilly. During his 25 years in the biopharmaceutical industry, Dr. Dere has led the clinical development of three bone-active medicines—raloxifene, rPTH 1-34, and denosumab—and several others in the oncology, inflammation, and nephrology therapeutic areas. He earned his B.A. and M.D. from University of California Davis and completed his residency at the University of Utah. Dr. Dere did his postdoctoral training, specializing in endocrinology and metabolism, at University of California San Francisco.
XIAOXIONG (JIM) WEI, M.D., PH.D.
Xiaoxiong “Jim” Wei, M.D., Ph.D., is the Medical Director of Clinical Pharmacology at Medpace, a clinical research organization (CRO). He has extensive expertise in regulatory strategy and early phase drug development, including study design. Previously Dr. Wei was a senior reviewer in the Office of Clinical Pharmacology for drug products in metabolic and endocrine fields at the Center for Drug Evaluation and Research (CDER) at the U. S. Food and Drug Administration (FDA) for nearly ten years, receiving an award for outstanding service in 2005. He was also an active member of both the Drug Metabolism & Drug Interaction and Pharmacogenetics Working Groups at the FDA. Prior to joining FDA, he was an IRTA fellow in the Laboratory of Metabolism at the National Cancer Institute (NCI) and National Institutes of Health (NIH). Dr. Wei received his Ph.D. in Pharmaceutical Sciences from Idaho State University and his medical degree from Zhejiang University School of Medicine.